Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Core Insights - Pfizer Inc. announced positive topline progression-free survival results from Cohort 3 of the pivotal BREAKWATER trial, which evaluated BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI in patients with previously untreated metastatic colorectal cancer with a BRAF V600E mutation [1] Group 1 - The BRAFTOVI regimen demonstrated statistically significant results in the trial [1]